Citius Pharmaceuticals, Inc. (CTXR)

0,9600 +0,0291 (+3,13%) Alla chiusura: 04:00PM EDT

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://citiuspharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 22

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary	676,88k	N/D	1945
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman	641,25k	N/D	1947
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer	571,38k	N/D	1960
Mr. Jaime Bartushak	Chief Business Officer, CFO & Chief Accounting Officer	527,97k	N/D	1968
Mr. Gary F. Talarico	Executive Vice President of Operations	N/D	N/D	1955
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance	N/D	N/D	N/D
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy	N/D	N/D	1954
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls	N/D	N/D	N/D
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Its biologics license application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma is under review by the FDA. Its LYMPHIR also received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, the company is developing CITI-002 (Halo-Lido), which is in Phase 2b trial for the relief of hemorrhoids. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Citius Pharmaceuticals, Inc. al 1 luglio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.